Hansa Biopharma Raises SEK 232 Million and Restructures Debt to Support Growth

The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).

Hansa Biopharma has successfully completed a directed cash share issue, raising approximately SEK 232 million, and has restructured its debt agreement with NovaQuest. This financial maneuver aims to support the company’s ongoing phase III trials for imlifidase and other pipeline projects, positioning Hansa for sustainable growth and strengthening its shareholder base. The restructuring of the NovaQuest agreement includes a set-off issue of USD 14.9 million in new shares and revised payment terms, which are expected to enhance the company’s financial flexibility and operational stability.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, focused on developing innovative treatments for rare immunological conditions. The company is known for its work on imlifidase, an enzyme used to enable kidney transplants in highly sensitized patients, and it is actively involved in advancing its pipeline projects.

Average Trading Volume: 157,282

Current Market Cap: SEK1.66B

Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.